- Home
- VTYX vs CRDL Comparison
VTYX vs CRDL Comparison
Compare VTYX & CRDL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VTYX
- CRDL
- Stock Information
- Founded
- VTYX 2018
- CRDL 2017
- Country
- VTYX United States
- CRDL Canada
- Employees
- VTYX N/A
- CRDL N/A
- Industry
- VTYX Medicinal Chemicals and Botanical Products
- CRDL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- VTYX Health Care
- CRDL Health Care
- Exchange
- VTYX Nasdaq
- CRDL Nasdaq
- Market Cap
- VTYX 154.9M
- CRDL 126.5M
- IPO Year
- VTYX 2021
- CRDL N/A
- Fundamental
- Price
- VTYX $2.30
- CRDL $1.07
- Analyst Decision
- VTYX Buy
- CRDL Strong Buy
- Analyst Count
- VTYX 2
- CRDL 2
- Target Price
- VTYX $9.00
- CRDL $9.00
- AVG Volume (30 Days)
- VTYX 441.6K
- CRDL 949.0K
- Earning Date
- VTYX 11-06-2025
- CRDL 11-13-2025
- Dividend Yield
- VTYX N/A
- CRDL N/A
- EPS Growth
- VTYX N/A
- CRDL N/A
- EPS
- VTYX N/A
- CRDL N/A
- Revenue
- VTYX N/A
- CRDL N/A
- Revenue This Year
- VTYX N/A
- CRDL N/A
- Revenue Next Year
- VTYX N/A
- CRDL N/A
- P/E Ratio
- VTYX N/A
- CRDL N/A
- Revenue Growth
- VTYX N/A
- CRDL N/A
- 52 Week Low
- VTYX $0.78
- CRDL $0.77
- 52 Week High
- VTYX $3.39
- CRDL $2.63
- Technical
- Relative Strength Index (RSI)
- VTYX 39.52
- CRDL 42.84
- Support Level
- VTYX $2.31
- CRDL $1.02
- Resistance Level
- VTYX $2.54
- CRDL $1.14
- Average True Range (ATR)
- VTYX 0.14
- CRDL 0.07
- MACD
- VTYX -0.02
- CRDL 0.00
- Stochastic Oscillator
- VTYX 0.00
- CRDL 27.78
About VTYX Ventyx Biosciences Inc.
Ventyx Biosciences Inc is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune disorders. The company is developing a pipeline of novel small-molecule product candidates to address a range of inflammatory diseases. Its product candidate VTX958 is an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor designed to inhibit TYK2 without detectable inhibition of other Janus kinase (JAK) isoforms, which avoids toxicities associated with broader JAK inhibition and, thus, other JAK inhibitors.
About CRDL Cardiol Therapeutics Inc.
Cardiol Therapeutics Inc is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart diseases. The company's main product candidate, CardiolRx, is a pharmaceutically manufactured oral cannabidiol formulation that is being clinically developed for use in heart diseases. Cardiol has received Investigational New Drug Application authorization from the United States Food and Drug Administration to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart which are a Phase II multi-national trial, the ARCHER trial, in acute myocarditis; and a Phase II multi-center open-label pilot study in recurrent pericarditis.